Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Group 1 - The core point of the article is that Jiu Ri New Materials announced the approval of its subsidiary's project for the production of 350 tons of hydroxy ketone series photoinitiators, which will enter trial production on January 13, 2026 [1] Group 2 - The project is located in Inner Mongolia and is part of the company's strategy to expand its production capabilities in the photoinitiator market [1] - The announcement comes amid challenges faced by the photovoltaic industry, where companies are struggling with rising raw material costs, leading to difficult decision-making [1]

Core Viewpoint - The company, Jiu Ri New Materials (688199), has announced the commencement of trial production for its "Inner Mongolia Hongyuan Tiancheng Technology Development Co., Ltd. Annual Production of 350 Tons of Hydroxyketone Series Photoinitiator Project" as of January 13, following approval from an expert review panel [1]. Group 1 - The trial production phase for the hydroxyketone series photoinitiators has officially started on January 13 [1]. - The hydroxyketone series products are expected to capture mainstream markets such as UV coatings/inks and 3D printing due to their high performance, low yellowing, and low odor advantages [1].

Core Viewpoint - The company has announced that its subsidiary, Inner Mongolia Hongyuan Tiancheng Technology Development Co., Ltd., has received expert group approval for the "Annual Production of 350 Tons of Hydroxyketone Series Photoinitiator Project," which is set to enter trial production on January 13, 2026. This project is expected to enhance the company's profitability and overall competitiveness in the market [1]. Group 1 - The hydroxyketone series products have competitive advantages in UV coatings, inks, and 3D printing sectors [1]. - The project utilizes advanced process equipment, which is anticipated to improve the company's profitability [1]. - The successful completion of the expert group review marks a significant milestone for the company's expansion in the photoinitiator market [1].

Fundraising Overview - The company successfully raised a total of RMB 185,415.74 million by issuing 27,806,800 shares at a price of RMB 66.68 per share, with a net amount of RMB 170,929.30 million after deducting issuance costs of RMB 14,486.45 million [1] Changes in Fundraising Projects - The company decided to reallocate RMB 48 million of unused fundraising to two new projects: a 1,500-ton acyl phosphine oxide series photoinitiator project and a 350-ton hydroxy ketone series photoinitiator project, with the approval from the board and shareholders [2][3] Fund Management and Supervision - The company established special fundraising accounts for the new projects and signed a tripartite supervision agreement with the banks and the sponsor to ensure compliance with fundraising management regulations [3][4] - The special accounts are designated solely for the respective projects, ensuring that funds are not used for other purposes [5][9] Agreement Details - The tripartite agreement outlines the responsibilities of each party, including the management of funds, supervision by the sponsor, and the requirement for monthly account statements [6][7] - The agreement will remain effective until all funds are utilized and the supervision period concludes [8][12]

Group 1 - The company Tianjin Jiuri New Materials Co., Ltd. has signed a tripartite supervision agreement for the management of raised funds [1][4] - The company raised a total of RMB 185,415.74 million by issuing 27,806,800 shares at a price of RMB 66.68 per share, with a net amount of RMB 170,929.30 million after deducting issuance costs [2][3] - The company has allocated RMB 48 million of unused raised funds to two new projects: a 1,500-ton acyl phosphine oxide series photoinitiator project and a 350-ton hydroxy ketone series photoinitiator project [3][4] Group 2 - The tripartite supervision agreement was signed on October 17, 2025, involving Tianjin Jiuri, its wholly-owned subsidiary Inner Mongolia Jiuri New Materials Co., Ltd., and the sponsor and bank [4][6] - The agreement stipulates that the funds must be stored in a special account solely for the designated projects and cannot be used for other purposes [6][10] - The sponsor has the right to supervise the use of the raised funds and must conduct semi-annual inspections of the fund management [7][11]

Core Viewpoint - The company has approved the use of part of its raised funds to provide a loan to its controlling subsidiary, which is aimed at implementing a fundraising investment project, thereby enhancing the efficiency of fund utilization [1][4][9]. Meeting Details - The fifth session of the company's supervisory board was held on October 13, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [1][2]. - The supervisory board unanimously approved the proposal to use part of the raised funds for the loan [2]. Fundraising and Loan Details - The company plans to provide a loan of 9 million RMB to its subsidiary, Inner Mongolia Hongyuan Tiancheng Technology Development Co., Ltd., for the implementation of a project to produce 350 tons of hydroxy ketone series photoinitiators annually [4][5]. - The total amount raised from the initial public offering was approximately 1.85 billion RMB, with a net amount of about 1.71 billion RMB after deducting issuance costs [5]. Purpose and Impact of the Loan - The loan is intended to ensure the smooth implementation of the fundraising investment project and aligns with the planned use of raised funds, without altering the intended use or harming shareholder interests [9][11]. - The subsidiary, Hongyuan Tiancheng, is financially stable and poses controllable financial risks [9]. Fund Management - The loan will be managed through a dedicated account for raised funds, with a tripartite supervision agreement signed among the company, the bank, and the sponsor [10]. - The loan interest rate will be determined based on the latest published loan market quotation rate and other factors, with a maximum term of 36 months [6]. Opinions from Supervisory Board and Sponsor - The supervisory board and the sponsor have expressed their agreement with the proposal, confirming compliance with relevant regulations and the company's fundraising management system [12].